Vanguard Capital Management
LENZ

Vanguard Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Vanguard Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.24M Buy
1,097,755
+56,567
+5% +$456K ﹤0.01% 3040
2026
Q1 		$9.53M Buy
+1,041,188
New +$14.6M ﹤0.01% 2758

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Vanguard Capital Management's LENZ Position: Q2 2026 in Review

Vanguard Capital Management increased its LENZ Therapeutics (LENZ) stake by 5.4% in Q2 2026, buying an estimated $456K and bringing the position to 1,097,755 shares worth $6.24M. The position accounts for ﹤0.01% of the portfolio, ranked #3040.

Vanguard Capital Management first reported a position in LENZ in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.53M in Q1 2026. 143 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Vanguard Capital Management held 1,097,755 shares of LENZ Therapeutics worth $6.24M as of Q2 2026.
  • Vanguard Capital Management bought 56,567 LENZ Therapeutics shares in Q2 2026, an estimated $456K.
  • LENZ Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3040 holding.
  • Vanguard Capital Management first reported a position in LENZ Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's LENZ Therapeutics position peaked at $9.53M in Q1 2026.
  • 143 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.